Long-term systemic angiotensin II type 1 receptor blockade regulates mRNA expression of dorsomedial medulla renin-angiotensin system components

Physiological Genomics

Volumn 43, Issue 13, 2011, Pages 829-835

  Gilliam Davis, Shea ^a   Gallagher, Patricia E ^a   Payne, Valerie S ^a   Kasper, Sherry O ^a   Tommasi, Ellen N ^a   Westwood, Brian M ^a   Robbins, Michael E ^a   Chappell, Mark C ^a   Diz, Debra I ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Aggregate correlate summation; Angiotensinogen; Fischer 344 rats; Leptin

Indexed keywords

2 ETHYL 5,7 DIMETHYL 3 [4 [2 (2H TETRAZOL 5 YL)PHENYL]BENZYL]IMIDAZO[4,5 B]PYRIDINE; ANGIOTENSIN 1B RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; MEMBRANE METALLOENDOPEPTIDASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; GENE EXPRESSION; MALE; MEDULLA OBLONGATA; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

AGING; ANGIOTENSINOGEN; ANIMALS; DUAL-SPECIFICITY PHOSPHATASES; GENE EXPRESSION REGULATION; IMIDAZOLES; LEPTIN; MALE; MEDIODORSAL THALAMIC NUCLEUS; PEPTIDYL-DIPEPTIDASE A; RATS; RATS, INBRED F344; RECEPTOR, ANGIOTENSIN, TYPE 1; REGRESSION ANALYSIS; RENIN-ANGIOTENSIN SYSTEM; RNA, MESSENGER; TETRAZOLES; TIME FACTORS;

RATTUS;

EID: 79960368372     PISSN: 10948341     EISSN: 15312267     Source Type: Journal    
DOI: 10.1152/physiolgenomics.00167.2010     Document Type: Article

References (45)

1. Major outcomes in high-risk hypertensive patients randomized to angiotensin- converting enzyme inhibitor or calcium channel blocker vs diuretic:the Antihypertensive, and Lipid-Lowering Treatment to Prevent Heart ttack Trial (ALLHAT). JAMA 288: 2981-2997, 2002.
2. Arnold AC, Sakima A, Ganten D, Ferrario CM, Diz DI. Modulation of eflex function by endogenous angiotensins in older transgenic rats with ow glial angiotensinogen. Hypertension 51: 1326-1331, 2008.
3. Awazu M, Ishikura K, Hida M, Hoshiya M. Mechanisms of mitogenactivated rotein kinase activation in experimental diabetes. J Am Soc Nephrol 10: 738-745, 1999.
4. Bader M, Ganten D. Update on tissue renin-angiotensin systems. J Mol ed 86: 615-621, 2008.
5. Carvalheira JB, Torsoni MA, Ueno M, Amaral ME, Araujo EP, elloso LA, Gontijo JA, Saad MJ. Cross-talk between the insulin and eptin signaling systems in rat hypothalamus. Obes Res 13: 48-57, 2005.
6. Chappell MC, Westwood BM, Yamaleyeva LM. Differential effects of ex steroids in young and aged female mRen2. Lewis rats: a model of strogen and salt-sensitive hypertension. Gend Med 5, Suppl A: S65-S75, 2008.
7. Culman J, Blume A, Gohlke P, Unger T. The renin-angiotensin system n the brain: possible therapeutic implications for AT(1)-receptor blockers. Hum Hypertens 16, Suppl 3: S64-S70, 2002.
8. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, yhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm H, Nieminen MS, Omvik P, Oparil S, Wedel H. Cardiovascular orbidity and mortality in the Losartan Intervention For Endpoint reduction n hypertension study (LIFE): a randomised trial against atenolol. ancet 359: 995-1003, 2002.
9. Diz DI, Garcia-Espinosa MA, Gegick S, Tommasi EN, Ferrario CM, nn TE, Chappell MC, Gallagher PE. Injections of angiotensin-converting nzyme 2 inhibitor MLN4760 into nucleus tractus solitarii reduce aroreceptor reflex sensitivity for heart rate control in rats. Exp Physiol 93: 694-700, 2008.
10. Elchebly M, Payette P, Michaliszyn E, Cromlish W, Collins S, Loy L, Normandin D, Cheng A, Himms-Hagen J, Chan CC, Ramachandran, Gresser MJ, Tremblay ML, Kennedy BP. Increased insulin ensitivity and obesity resistance in mice lacking the protein tyrosine hosphatase-1B gene. Science 283: 1544-1548, 1999.
11. Farooq A, Zhou MM. Structure and regulation of MAPK phosphatases. Cell Signal 16: 769-779, 2004.
12. Fischer TA, Singh K, O'Hara DS, Kaye DM, Kelly RA. Role of AT1 and AT2 receptors in regulation of MAPKs and MKP-1 by ANG II in adult cardiac myocytes. Am J Physiol Heart Circ Physiol 275: H906-H916, 1998.
13. Gallagher PE, Ferrario CM, Tallant EA. MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides. Am J Physiol Cell Physiol 295: C1169-C1174, 2008.
14. Garcia-Espinosa MA, Shaltout HA, Olson J, Westwood BM, Robbins ME, Link K, Diz DI. Proton magnetic resonance spectroscopy detectionof neurotransmitters in dorsomedial medulla correlate with spontaneous baroreceptor reflex function. Hypertension 55: 487-493, 2010.
15. Giani JF, Mayer MA, Munoz MC, Silberman EA, Hocht C, Taira CA, Gironacci MM, Turyn D, Dominici FP. Chronic infusion of angiotensin- (1-7) improves insulin resistance and hypertension induced by a highfructose diet in rats. Am J Physiol Endocrinol Metab 296: E262-E271, 2009.
16. Gilliam-Davis S, Payne VS, Kasper SO, Tommasi EN, Robbins ME, Diz DI. Long-term AT1 receptor blockade improves metabolic function and provides renoprotection in Fischer-344 rats. Am J Physiol Heart Circ Physiol 293: H1327-H1333, 2007.
17. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353: 611-616, 1999.
18. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M. Selective angiotensin II receptor receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 38: 884-890, 2001.
19. Hiroi Y, Hiroi J, Kudoh S, Yazaki Y, Nagai R, Komuro I. Two distinct mechanisms of angiotensin II-induced negative regulation of the mitogenactivated protein kinases in cultured cardiac myocytes. Hypertens Res 24: 385-394, 2001.
20. Kasper SO, Carter CS, Ferrario CM, Ganten D, Ferder LF, Sonntag WE, Gallagher PE, Diz DI. Growth, metabolism, and blood pressure disturbances during aging in transgenic rats with altered brain reninangiotensin systems. Physiol Genomics 23: 311-317, 2005.
21. Kasper SO, Ferrario CM, Ganten D, Diz DI. Rats with low brain angiotensinogen do not exhibit insulin resistance during early aging. Endocrine 30: 167-174, 2006.
22. Kennedy BP, Ramachandran C. Protein tyrosine phosphatase-1B in diabetes. Biochem Pharmacol 60: 877-883, 2000.
23. Klaman LD, Boss O, Peroni OD, Kim JK, Martino JL, Zabolotny JM, Moghal N, Lubkin M, Kim YB, Sharpe AH, Stricker-Krongrad A, Shulman GI, Neel BG, Kahn BB. Increased energy expenditure, decreased adiposity, and tissue-specific insulin ensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol Cell Biol 20: 5479-5489, 2000.
24. Kusari AB, Byon J, Bandyopadhyay D, Kenner KA, Kusari J. Insulininduced mitogen-activated protein (MAP) kinase phosphatase-1 (MKP-1) attenuates insulin-stimulated MAP kinase activity: a mechanism for the feedback inhibition of insulin signaling. Mol Endocrinol 11: 1532-1543, 1997.
25. Lavoie JL, Sigmund CD. Minireview: overview of the renin-angiotensin system-an endocrine and paracrine system. Endocrinology 144: 2179-2183, 2003.
26. Lemarie CA, Schiffrin EL. The angiotensin II type 2 receptor in cardiovascular disease. J Renin Angiotensin Aldosterone Syst 11: 19-31, 2010.
27. Morimoto S, Cassell MD, Beltz TG, Johnson AK, Davisson RL, Sigmund CD. Elevated blood pressure in transgenic mice with brainspecific expression of human angiotensinogen driven by the glial fibrillary acidic protein promoter. Circ Res 89: 365-372, 2001.
28. Morimoto S, Cassell MD, Sigmund CD. Glia- and neuron-specific expression of the renin-angiotensin system in brain alters blood pressure, water intake, and salt preference. J Biol Chem 277: 33235-33241, 2002.
29. Nishimura M, Takahashi H, Yoshimura M. Upregulation of the brain renin-angiotensin system in rats with chronic renal failure. Acta Physiol (Oxf) 189: 369-377, 2007.
30. Oden SD, Ganten D, Ferrario CM, Chappell MC, Diz DI. Rats with low brain angiotensinogen maintain normal levels of insulin and components of the circulating and intra-renal renin-angiotensin systems during aging (Abstract). FASEB J 18: A738, 2004.
31. Owens DM, Keyse SM. Differential regulation of MAP kinase signaling by dual-specificity protein phosphatases. Oncogene 26: 3203-3213, 2007.
32. Prasad A, Quyyumi AA. Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation 110: 1507-1512,2004.
33. Sangaleti CT, Crescenzi A, Michelini LC. Endogenous angiotensin and pressure modulate brain angiotensinogen and AT1A mRNA expression. Hypertension 43: 317-323, 2004.
34. Santos SH, Fernandes LR, Mario EG, Ferreira AV, Porto LC, Alvarez- Leite JI, Botion LM, Bader M, Alenina N, Santos RA. Mas deficiency in FVB/N mice produces marked changes in lipid and glycemic metabolism. Diabetes 57: 340-347, 2008.
35. Shiuchi T, Iwai M, Li HS, Wu L, Min LJ, Li JM, Okumura M, Cui TX, Horiuchi M. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 43: 1003-1010, 2004.
36. Steckelings U, Lebrun C, Qadri F, Veltmar A, Unger T. Role of brain angiotensin in cardiovascular regulation. J Cardiovasc Pharmacol 19, Suppl 6: S72-S79, 1992.
37. Takehara N, Kawabe J, Aizawa Y, Hasebe N, Kikuchi K. High glucose attenuates insulin-induced mitogen-activated protein kinase phosphatase-1 (MKP-1) expression in vascular smooth muscle cells. Biochim Biophys Acta 1497: 244-252, 2000.
38. van den Meiracker AH, Boomsma F. The angiotensin II-sympathetic nervous system connection. J Hypertens 21: 1453-1454, 2003.
39. Velloso LA, Folli F, Perego L, Saad MJ. The multi-faceted cross-talk between the insulin and angiotensin II signaling systems. Diabetes Metab Res Rev 22: 98-107, 2006.
40. Velloso LA, Folli F, Sun XJ, White MF, Saad MJ, Kahn CR. Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci USA 93: 12490-12495, 1996.
41. Weng Y, Shen F, Li J, Shen Y, Zhang X. Expression changes of mitogen-activated protein kinase phosphatase-1 (MKP-1) in myocardium of streptozotocin-induced diabetic rats. Exp Clin Endocrinol Diabetes 115: 455-460, 2007.
42. Westwood B, Chappell MC. Application of correlate summation to data clustering in the estrogen- and salt-sensitive female mRen2 Lewis rat. TMBIO 21-25, 2006.
43. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342: 145-153, 2000.
44. Zhou J, Pavel J, Macova M, Yu ZX, Imboden H, Ge L, Nishioku T, Dou J, Delgiacco E, Saavedra JM. AT1 receptor blockade regulates the local angiotensin II system in cerebral microvessels from spontaneously hypertensive rats. Stroke 37: 1271-1276, 2006.
45. Zhou J, Wang L, Ling S, Zhang X. Expression changes of growthassociated protein-43 (GAP-43) and mitogen-activated protein kinase phosphatase-1 (MKP-1) and in hippocampus of streptozotocin-induced diabetic cognitive impairment rats. Exp Neurol 206: 201-208, 2007.